AIM: To compare the need for infliximab dose intensification in two cohorts of patients with Crohn's disease (CD) or ulcerative colitis (UC). METHODS: Single centre, uncontrolled, observational study. Consecutive patients with CD and UC who responded to infliximab induction doses were included. Data collected in a prospectively maintained database were retrospectively analysed. Differences in the rates of dose intensification per patient-month and the intensification-free survival time were compared. We also evaluated the interval between the first infliximab induction dose and the first infliximab escalated dose. The weight-adjusted infliximab administration costs were also calculated. RESULTS: Fifty nine patients with CD and 38 patients with UC were enrolled. The rate of intensification per patient-month was 3.9% for UC and 1.4% for CD (P = 0.005). The median time from baseline to intensification was significantly shorter in UC compared to CD [6.6 mo (IQR: 4.2-9.5 mo) vs 10.7 mo (IQR: 8.9-11.7 mo), P = 0.005]. In the survival analysis, the cumulative probability of avoiding infliximab dose intensification was significantly higher in CD (P = 0.002). In the multivariate analysis, disease (UC vs CD) was the only factor significantly associated with dose intensification. The infiximab administration costs during the first year were significantly higher for UC compared to CD (mean ± SD 234.9 ± 53.3 Euros/kg vs 212.3 ± 15.1 Euros/kg, P = 0.03). CONCLUSION: The rate of infliximab dose intensification per patient-month is significantly higher in UC patients. The infliximab administration costs are also significantly higher in patients with UC.
AIM: To compare the need for infliximab dose intensification in two cohorts of patients with Crohn's disease (CD) or ulcerative colitis (UC). METHODS: Single centre, uncontrolled, observational study. Consecutive patients with CD and UC who responded to infliximab induction doses were included. Data collected in a prospectively maintained database were retrospectively analysed. Differences in the rates of dose intensification per patient-month and the intensification-free survival time were compared. We also evaluated the interval between the first infliximab induction dose and the first infliximab escalated dose. The weight-adjusted infliximab administration costs were also calculated. RESULTS: Fifty nine patients with CD and 38 patients with UC were enrolled. The rate of intensification per patient-month was 3.9% for UC and 1.4% for CD (P = 0.005). The median time from baseline to intensification was significantly shorter in UC compared to CD [6.6 mo (IQR: 4.2-9.5 mo) vs 10.7 mo (IQR: 8.9-11.7 mo), P = 0.005]. In the survival analysis, the cumulative probability of avoiding infliximab dose intensification was significantly higher in CD (P = 0.002). In the multivariate analysis, disease (UC vs CD) was the only factor significantly associated with dose intensification. The infiximab administration costs during the first year were significantly higher for UC compared to CD (mean ± SD 234.9 ± 53.3 Euros/kg vs 212.3 ± 15.1 Euros/kg, P = 0.03). CONCLUSION: The rate of infliximab dose intensification per patient-month is significantly higher in UC patients. The infliximab administration costs are also significantly higher in patients with UC.
Authors: Walter Reinisch; William J Sandborn; Paul Rutgeerts; Brian G Feagan; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Marion Blank; Yinghua Lang; Jewel Johanns; Jean Frédéric Colombel; Daniel Present; Bruce E Sands Journal: Inflamm Bowel Dis Date: 2011-04-11 Impact factor: 5.325
Authors: C Taxonera; J Estellés; I Fernández-Blanco; O Merino; I Marín-Jiménez; M Barreiro-de Acosta; C Saro; V García-Sánchez; E Gento; G Bastida; J P Gisbert; I Vera; P Martinez-Montiel; S Garcia-Morán; M C Sánchez; J L Mendoza Journal: Aliment Pharmacol Ther Date: 2010-12-07 Impact factor: 8.171
Authors: William J Sandborn; Paul Rutgeerts; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Jiandong Lu; Kevin Horgan; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: Gastroenterology Date: 2009-07-28 Impact factor: 22.682
Authors: Carlos Taxonera; Manuel Barreiro-de Acosta; Marta Calvo; Cristina Saro; Guillermo Bastida; María D Martín-Arranz; Javier P Gisbert; Valle García-Sánchez; Ignacio Marín-Jiménez; Fernando Bermejo; María Chaparro; Ángel Ponferrada; María P Martínez-Montiel; Ramón Pajares; Celia de Gracia; David Olivares; Cristina Alba; Juan L Mendoza; Ignacio Fernández-Blanco Journal: Dig Dis Sci Date: 2015-06-05 Impact factor: 3.199
Authors: Milena Oliveira Freitas; Alline Pereira Rodrigues Fonseca; Maria Thaynara de Aguiar; Camila Costa Dias; Rafael Linard Avelar; Fabrício Bitu Sousa; Ana Paula Negreiros Nunes Alves; Paulo Goberlânio de Barros Silva Journal: Inflammopharmacology Date: 2022-08-10 Impact factor: 5.093
Authors: Jan Marsal; Manuel Barreiro-de Acosta; Irina Blumenstein; Maria Cappello; Thomas Bazin; Shaji Sebastian Journal: Front Med (Lausanne) Date: 2022-06-15